Pharmacokinetics and pharmacodynamics of dapagliflozin in children and adolescents with type 2 diabetes mellitus

Aims To evaluate the pharmacokinetic ( PK )/pharmacodynamic ( PD ) and safety profile of dapagliflozin in paediatric patients aged 10–17 years with type 2 diabetes mellitus ( T2DM ). Methods Patients were randomized to a single oral dose of dapagliflozin 2.5, 5 or 10 mg. The PK characteristics for individual patients were derived by non‐compartmental methods. Urinary glucose excretion ( UGE ), fasting plasma glucose ( FPG ) and ease of...